The mycosis fungoides treatment market size has grown strongly in recent years. It will grow from $0.91 billion in 2023 to $0.97 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth observed in the historic period can be attributed to several factors, including increased incidences of immune system dysfunction leading to a higher demand for effective therapeutics, widespread adoption of phototherapy as a treatment modality, increased utilization of radiation therapy, and the growing popularity of supportive care measures aimed at managing symptoms and improving patient outcomes.
The mycosis fungoides treatment market size is expected to see strong growth in the next few years. It will grow to $1.26 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The anticipated growth in the forecast period is expected to be driven by advancements in healthcare infrastructure, a growing patient population, and an increase in the prevalence of mycosis fungoides possibly due to unhygienic lifestyles. Major trends projected for this period encompass technological advancements in treatment options related to chemotherapy, an uptick in the demand for monoclonal antibodies as first-line therapy, the introduction of new advanced products into the market, and an increasing focus on investment in research and development efforts.
The increasing incidence of lymphoma cancer is expected to drive the expansion of the mycosis fungoides treatment market in the future. Lymphoma, a cancer affecting the lymphatic system comprising lymph nodes, spleen, thymus gland, and bone marrow, is on the rise due to various factors such as environmental exposures, viral infections, an aging population, and lifestyle choices. Mycosis fungoides treatments, including topical corticosteroids, phototherapy, and systemic therapies, are utilized in managing cutaneous T-cell lymphomas to control skin lesions, alleviate symptoms, and manage disease progression in lymphoma patients. For example, in January 2024, according to the American Cancer Society, non-Hodgkin lymphoma (NHL) ranked among the most prevalent cancers in the United States, constituting about 4% of all cancer cases. It was estimated that around 80,620 individuals (44,590 males and 36,030 females) would be diagnosed with NHL, with approximately 20,140 people (11,780 males and 8,360 females) succumbing to this cancer in 2024. Hence, the increasing incidence of lymphoma cancer is fueling the growth of the mycosis fungoides treatment market.
Key players in the mycosis fungoides treatment market are focusing on developing advanced therapies such as CAR T cell therapy to enhance treatment efficacy and specificity. CAR T cell therapy, a form of immunotherapy, involves genetically modifying a patient's T cells to better recognize and target cancer cells, including those associated with mycosis fungoides. For instance, in September 2022, CRISPR Therapeutics AG, a Switzerland-based biotech company, announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130, the company’s allogeneic CAR T cell therapy targeting CD70, for treating Mycosis Fungoides and Sézary Syndrome (MF or SS). This designation signifies a significant milestone for the CTX130 program, acknowledging the potential of this cell therapy in treating T-cell lymphomas based on promising clinical data. The RMAT designation is part of a program established under the 21st Century Cures Act to expedite drug development and review processes for genetic therapies intended to treat severe or life-threatening diseases.
In November 2021, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Trillium Therapeutics for approximately $2.22 billion, strengthening its presence in oncology, expanding its hematology portfolio, and gaining access to innovative therapies. Trillium Therapeutics, a U.S.-based immuno-oncology company, focuses on developing treatments for mycosis fungoides.
Major companies operating in the mycosis fungoides treatment market are Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Tocris Bioscience, Viatris Inc., Astellas Pharma Inc., Daiichi Sankyo Company, Takeda Pharmaceutical Company Limited, Bausch Health, Eisai Co. Ltd., Horizon Therapeutics plc, Varian Medical Systems, Kyowa Kirin Co. Ltd., Seattle Genetics Inc., Azurity Pharmaceuticals Inc., Innate Pharma S.A., Helsinn Therapeutics, Jubilant Cadista Pharmaceuticals Inc., Elorac Inc., Soligenix Inc., Ceptaris Therapeutics Inc.
North America was the largest region in the mycosis fungoides treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mycosis fungoides treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mycosis fungoides treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Mycosis fungoides treatment encompasses a range of therapies, medications, and procedures aimed at managing and alleviating symptoms associated with cutaneous T-cell lymphoma, a rare type of non-Hodgkin lymphoma primarily affecting the skin. Treatment approaches typically involve a combination of therapies, including topical medications and systemic treatments such as immunotherapy, tailored to the specific stage and severity of the disease.
The primary types of mycosis fungoides treatment include topical steroids and mechlorethamine. Topical steroids are applied directly to the skin to reduce inflammation and irritation. Other treatment modalities encompass photodynamic therapy, radiation therapy, targeted therapy, and chemotherapy, utilized across various healthcare settings such as hospitals, private clinics, and specialty clinics.
The mycosis fungoides treatment market research report is one of a series of new reports that provides mycosis fungoides treatment market statistics, including mycosis fungoides treatment industry global market size, regional shares, competitors with a mycosis fungoides treatment market share, detailed mycosis fungoides treatment market segments, market trends and opportunities, and any further data you may need to thrive in the mycosis fungoides treatment industry. This mycosis fungoides treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The mycosis fungoides treatment market consists of revenues earned by entities by providing services, such as phototherapy, dermatological care, and specialized therapies. The market value includes the value of related services provided by the treatment creators or included within the treatment offering. The mycosis fungoides treatment market also includes sales of oral retinoids, interferons, monoclonal antibodies, and nitrogen mustard. Values in this market are ‘factory gate’ values, that is, the value of treatments sold by the manufacturers or creators of the treatments, whether to other entities (including downstream healthcare providers and pharmacies) or directly to end customers. The value of treatments in this market includes related services sold by the creators of the treatments.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The mycosis fungoides treatment market size is expected to see strong growth in the next few years. It will grow to $1.26 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The anticipated growth in the forecast period is expected to be driven by advancements in healthcare infrastructure, a growing patient population, and an increase in the prevalence of mycosis fungoides possibly due to unhygienic lifestyles. Major trends projected for this period encompass technological advancements in treatment options related to chemotherapy, an uptick in the demand for monoclonal antibodies as first-line therapy, the introduction of new advanced products into the market, and an increasing focus on investment in research and development efforts.
The increasing incidence of lymphoma cancer is expected to drive the expansion of the mycosis fungoides treatment market in the future. Lymphoma, a cancer affecting the lymphatic system comprising lymph nodes, spleen, thymus gland, and bone marrow, is on the rise due to various factors such as environmental exposures, viral infections, an aging population, and lifestyle choices. Mycosis fungoides treatments, including topical corticosteroids, phototherapy, and systemic therapies, are utilized in managing cutaneous T-cell lymphomas to control skin lesions, alleviate symptoms, and manage disease progression in lymphoma patients. For example, in January 2024, according to the American Cancer Society, non-Hodgkin lymphoma (NHL) ranked among the most prevalent cancers in the United States, constituting about 4% of all cancer cases. It was estimated that around 80,620 individuals (44,590 males and 36,030 females) would be diagnosed with NHL, with approximately 20,140 people (11,780 males and 8,360 females) succumbing to this cancer in 2024. Hence, the increasing incidence of lymphoma cancer is fueling the growth of the mycosis fungoides treatment market.
Key players in the mycosis fungoides treatment market are focusing on developing advanced therapies such as CAR T cell therapy to enhance treatment efficacy and specificity. CAR T cell therapy, a form of immunotherapy, involves genetically modifying a patient's T cells to better recognize and target cancer cells, including those associated with mycosis fungoides. For instance, in September 2022, CRISPR Therapeutics AG, a Switzerland-based biotech company, announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130, the company’s allogeneic CAR T cell therapy targeting CD70, for treating Mycosis Fungoides and Sézary Syndrome (MF or SS). This designation signifies a significant milestone for the CTX130 program, acknowledging the potential of this cell therapy in treating T-cell lymphomas based on promising clinical data. The RMAT designation is part of a program established under the 21st Century Cures Act to expedite drug development and review processes for genetic therapies intended to treat severe or life-threatening diseases.
In November 2021, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Trillium Therapeutics for approximately $2.22 billion, strengthening its presence in oncology, expanding its hematology portfolio, and gaining access to innovative therapies. Trillium Therapeutics, a U.S.-based immuno-oncology company, focuses on developing treatments for mycosis fungoides.
Major companies operating in the mycosis fungoides treatment market are Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Tocris Bioscience, Viatris Inc., Astellas Pharma Inc., Daiichi Sankyo Company, Takeda Pharmaceutical Company Limited, Bausch Health, Eisai Co. Ltd., Horizon Therapeutics plc, Varian Medical Systems, Kyowa Kirin Co. Ltd., Seattle Genetics Inc., Azurity Pharmaceuticals Inc., Innate Pharma S.A., Helsinn Therapeutics, Jubilant Cadista Pharmaceuticals Inc., Elorac Inc., Soligenix Inc., Ceptaris Therapeutics Inc.
North America was the largest region in the mycosis fungoides treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mycosis fungoides treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mycosis fungoides treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Mycosis fungoides treatment encompasses a range of therapies, medications, and procedures aimed at managing and alleviating symptoms associated with cutaneous T-cell lymphoma, a rare type of non-Hodgkin lymphoma primarily affecting the skin. Treatment approaches typically involve a combination of therapies, including topical medications and systemic treatments such as immunotherapy, tailored to the specific stage and severity of the disease.
The primary types of mycosis fungoides treatment include topical steroids and mechlorethamine. Topical steroids are applied directly to the skin to reduce inflammation and irritation. Other treatment modalities encompass photodynamic therapy, radiation therapy, targeted therapy, and chemotherapy, utilized across various healthcare settings such as hospitals, private clinics, and specialty clinics.
The mycosis fungoides treatment market research report is one of a series of new reports that provides mycosis fungoides treatment market statistics, including mycosis fungoides treatment industry global market size, regional shares, competitors with a mycosis fungoides treatment market share, detailed mycosis fungoides treatment market segments, market trends and opportunities, and any further data you may need to thrive in the mycosis fungoides treatment industry. This mycosis fungoides treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The mycosis fungoides treatment market consists of revenues earned by entities by providing services, such as phototherapy, dermatological care, and specialized therapies. The market value includes the value of related services provided by the treatment creators or included within the treatment offering. The mycosis fungoides treatment market also includes sales of oral retinoids, interferons, monoclonal antibodies, and nitrogen mustard. Values in this market are ‘factory gate’ values, that is, the value of treatments sold by the manufacturers or creators of the treatments, whether to other entities (including downstream healthcare providers and pharmacies) or directly to end customers. The value of treatments in this market includes related services sold by the creators of the treatments.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Mycosis Fungoides Treatment Market Characteristics3. Mycosis Fungoides Treatment Market Trends and Strategies32. Global Mycosis Fungoides Treatment Market Competitive Benchmarking33. Global Mycosis Fungoides Treatment Market Competitive Dashboard34. Key Mergers and Acquisitions in the Mycosis Fungoides Treatment Market
4. Mycosis Fungoides Treatment Market - Macro Economic Scenario
5. Global Mycosis Fungoides Treatment Market Size and Growth
6. Mycosis Fungoides Treatment Market Segmentation
7. Mycosis Fungoides Treatment Market Regional and Country Analysis
8. Asia-Pacific Mycosis Fungoides Treatment Market
9. China Mycosis Fungoides Treatment Market
10. India Mycosis Fungoides Treatment Market
11. Japan Mycosis Fungoides Treatment Market
12. Australia Mycosis Fungoides Treatment Market
13. Indonesia Mycosis Fungoides Treatment Market
14. South Korea Mycosis Fungoides Treatment Market
15. Western Europe Mycosis Fungoides Treatment Market
16. UK Mycosis Fungoides Treatment Market
17. Germany Mycosis Fungoides Treatment Market
18. France Mycosis Fungoides Treatment Market
19. Italy Mycosis Fungoides Treatment Market
20. Spain Mycosis Fungoides Treatment Market
21. Eastern Europe Mycosis Fungoides Treatment Market
22. Russia Mycosis Fungoides Treatment Market
23. North America Mycosis Fungoides Treatment Market
24. USA Mycosis Fungoides Treatment Market
25. Canada Mycosis Fungoides Treatment Market
26. South America Mycosis Fungoides Treatment Market
27. Brazil Mycosis Fungoides Treatment Market
28. Middle East Mycosis Fungoides Treatment Market
29. Africa Mycosis Fungoides Treatment Market
30. Mycosis Fungoides Treatment Market Competitive Landscape and Company Profiles
31. Mycosis Fungoides Treatment Market Other Major and Innovative Companies
35. Mycosis Fungoides Treatment Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Mycosis Fungoides Treatment Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on mycosis fungoides treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for mycosis fungoides treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The mycosis fungoides treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Type: Topical Steroids; Mechlorethamine2) By Treatment Type: Photodynamic Therapy; Radiation Therapy; Targeted Therapy; Chemotherapy
3) By End-user: Hospitals; Private Clinics; Specialty Clinics
Key Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Bristol Myers Squibb; Abbott Laboratories; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc.
- Merck & Co. Inc.
- Bristol Myers Squibb
- Abbott Laboratories
- Novartis AG
- GlaxoSmithKline plc
- Tocris Bioscience
- Viatris Inc.
- Astellas Pharma Inc.
- Daiichi Sankyo Company
- Takeda Pharmaceutical Company Limited
- Bausch Health
- Eisai Co. Ltd.
- Horizon Therapeutics plc
- Varian Medical Systems
- Kyowa Kirin Co. Ltd.
- Seattle Genetics Inc.
- Azurity Pharmaceuticals Inc.
- Innate Pharma S.A.
- Helsinn Therapeutics
- Jubilant Cadista Pharmaceuticals Inc.
- Elorac Inc.
- Soligenix Inc.
- Ceptaris Therapeutics Inc.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | July 2024 |
Forecast Period | 2024 - 2028 |
Estimated Market Value ( USD | $ 0.97 Billion |
Forecasted Market Value ( USD | $ 1.26 Billion |
Compound Annual Growth Rate | 6.9% |
Regions Covered | Global |